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Heterogeneity of Hepatitis  C  Virus  Genotypes  in  Hemophilia: 
Relationship  With  Chronic  Liver  Disease 
By F.E. Preston, L.M. Jarvis, M. Makris, L. Philp, J.C.E. Underwood, C.A. Ludlam,  and P. Simmonds 
In this study we have determined the hepatitis C  virus (HCV) 
serotype  and  genotype in a  cohort of 96 HCV-infected  hemo- 
philiacs  and have examined the relationship between HCV 
genotype  and  severity of  chronic liver  disease  as determined 
by liver biopsy. HCV serotype was determined by specific 
enzyme-linked immunosorbent assays (ELISAs) and geno- 
type by restriction fragment length polymorphism (RFLP) 
and  HCV viral sequencing.  The pattern of genotype  distribu- 
tion was quite unlike that of  HCV-infected United Kingdom 
(UK) blood donors in that five of the six known HCV  geno- 
types were represented,  50% were type 1, 13% type 2,  and 
18% type 3. An unexpected  observation was the presence 
of HCV genotype 4 in four patients and type 5 in two pa- 
HERE IS NOW general acceptance that the hepatitis 
C virus (HCV) is the cause of virtually all cases of 
posttransfusion hepatitis in  western countries and  is responsi- 
ble for most of the observed chronic liver disease in treated 
hemophiliacs. Most of the early reports of hepatic dysfunc- 
tion in hemophiliacs coincided with the introduction of clot- 
ting factor concentrates in the early 1970s,’.* and it is now 
clear that before the widespread adoption of effective antivi- 
ral treatment of these products in the mid 1980’s they  were 
largely responsible for the transmission of HCV  in the hemo- 
philia population. This view receives support from the obser- 
vation that virtually 100% of treated hemophiliacs are HCV 
antibody positive by second generation  assay^.^ 
HCV has been classified into a number of distinct groups 
or genotypes on  the basis of sequence similarities of com- 
plete genomic sequences4 or fragments amplified by poly- 
merase chain reaction (PCR).’,6 All known variants can be 
classified into a total of six major genotypes (types 1 through 
6), each with a variable number of more closely related 
subtypes.’ The six major genotypes have distinct nucleotide 
sequence in the 5’ noncoding region (NCR).8.9 Therefore, 
viruses can be typed by restriction fragment length polymor- 
phism (RFLP) analysis of DNA  amplified  from this region 
of the HCV genome.” 
Single batches of clotting factor concentrates are derived 
from tens of thousands of donor units  and regularly treated 
patients will have been exposed to high concentrations of 
virus. In addition, it is likely that  mixed infection will  be a 
feature of HCV infection hemophilia. 
In this study, we have used (1) RFLP, (2) specific ELISAs 
using synthetic HCV viral peptides, and (3) HCV viral se- 
quencing to determine the HCV genotypes of 96 HCV-in- 
fected hemophiliacs. We have also attempted to relate viral 
genotype to the severity of chronic liver disease determined 
by liver biopsy, clinical progression, and liver enzyme deter- 
mination. 
T 
MATERIALS AND METHODS 
Our cohort comprises 96 hepatitis C positive patients with familial 
hemorrhagic disorders treated in Sheffield, UK. All but four received 
nonvirally inactivated concentrates during the period 1972 to 1985. 
The other four patients received heat-treated products clearly impli- 
cated in HCV transmission.” Patients with hemophilia B received 
nonvirally inactivated prothrombin complex concentrates derived 
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tients. An additional feature was the presence  of mixed in- 
fection, detected in 14% and  7% by serotype  and  genotype 
analysis,  respectively.  Liver  biopsies were available from 51 
patients.  Cirrhosis was present in five of  27 (19%) of  individu- 
als with type 1, in 2 of 9 (22%) with type 2, and  5  of  8 ( 6 3 % )  
of those with type 3. The heterogeneous pattern of HCV 
genotype  distribution in this cohort of patients and the ob- 
served  relationship between the severity  of the related liver 
disease  and  specific  HCV  genotype may have important im- 
plications with respect to the natural history  and treatment 
of HCV-related  chronic  liver  disease in infected  hemophiliacs 
worldwide. 
0 1995 by The  American  Society of Hematology. 
from volunteer UK donors only, whereas the remainder of  the cohort 
received both commercial and noncommercial factor concentrates 
and in the latter group, those patients on regular treatment were 
exposed to  a variety  of different products. 
All subjects have been followed prospectively. Patients with se- 
vere hemophilia (A  and B) were reviewed at least three times a year, 
while the others (including those with von Willebrand’s disease) 
were reviewed annually. Liver enzyme determination was performed 
at each visit. Alanine transferase (ALT) concentrations were consid- 
ered persistently raised when all three most recent measurements 
were high, intermittently raised when one or two of the last three 
values were high, or normal  when none of  the last three estimations 
was above the upper limit of the  normal range. 
Liver biopsy samples were available from 51 of the 96 patients 
in the study. For those patients who  had more than one biopsy, only 
the  most recent one is considered. Forty-one biopsies were obtained 
as a diagnostic procedure, and 10 were obtained at autopsy. All 
were reviewed and categorized histologically by one pathologist 
(J.C.E.U.). 
RNA Extraction 
Virus RNA was extracted from 0.5 mL of stored sera after pel- 
leting of the virus by centrifugation at 100,OOOg for 90 minutes at 
4”C, incubation at 37°C for 2 hours with 1 mg/mL proteinase K in 
the presence of 40 wg/mL polyadenylic acid, 0.5% sodium dodecyl 
sulphate, 0.1 molL NaCI, 50 mmol/L Tris HCI (pH 8.0), and 1 
mmolL EDTA. RNA  was extracted with phenol, and after centrifu- 
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gation the supernatant was re-extracted successively with phenol/ 
chloroform ( 1  : 1 )  and chloroform/isoamylalcohol(50: I). Nucleic  acid 
was precipitated by the addition of 0.1 v01 of sodium acetate (pH 
5.2) and 2 v01 of ethanol. The dried pellet was resuspended in 25 
pL of diethylpyrocarbonate  (DEPC)-treated  water. 
HCV  Typing 
RNA  was reverse-transcribed and  amplified  using  nested  primers 
matching  conserved  regions in the 5' NCR as previously de~cribed.~ 
Amplification of  HCV  RNA  was  performed  using  outer  primers 209 
and 939 for the primary PCR and inner primers 21 1 and 940 for 
secondary  PCR.'  Twenty-five-microliter  aliquots of product  DNA 
were cleaved with the restriction enzymes HaeIIIIRsaI and MvaV 
HinjI,'" and the fragments  separated by agarose  gel  electrophoresis 
using 4% Metaphor agarose (FMC Bioproducts, Rockland, ME). 
The cleavage  patterns  in the 5' NCR  amplified by PCR  varied  con- 
siderably  between  the  major  types of HCV, and it was possible to 
identify  all  six  major  genotypes with this  system. 
Direct  nucleotide  sequencing of PCR  products  was  performed as 
described' with the exception that DNA was purified using Magic 
PCR preps DNA purification systems (Promega,  Madison, W1). 
Serum  samples  were  tested  for  type-specific  antibody by an indi- 
rect ELISA'* with  the  modification  that  the  sample  was  added  at a 
1/10 dilution  to  antigen-coated  and  blocked  wells,  and the first  incu- 
bation  carried out at  4°C overnight. 
Statistics 
Fisher's  exact test with Yates'  continuity  correction  was used to 
test differences between groups. 
RESULTS 
Liver  Function  Tests 
Persistently abnormal  ALT levels  were observed in 56% 
of HCV genotype 1 patients, 75% of type 2, and 88% of 
type 3. Intermittently abnormal results were  seen  in  27% of 
type 1, 25% of type 2, and in only one patient with HCV 
genotype 3. Normal ALT levels were observed in 17% of 
type 1 subjects, in a single patient only  with  type  3,  and in 
three of six  PCR  negative patients.  Of the  other  three  PCR 
negative subjects, persistently abnormal liver enzymes  were 
seen in two,  and intermittent abnormalities in one. 
Liver  Histology 
Biopsy specimens  from  28 patients were classified as 
chronic persistent hepatitis, 10 as chronic active hepatitis, 
and 13 as  cirrhosis. One  patient  who  was  PCR  negative  had 
chronic persistent  hepatitis. 
HCV  Serotypes 
Results of the HCV  typing  studies are presented  in Table 
1.  Of  the 96 hemophiliacs tested, 59% were  serotype 1, 2% 
type  2,  and 5% type 3. Mixed  serotypes  were  demonstrated 
in 14%.  In 19 cases  (20%),  the  serotype  could  not  be deter- 
mined by ELISA. 
HCV Genotypes 
As indicated  in Table 1 ,  there  was  considerable  dis- 
cordance between individual genotype and serotype, and 
identical results were observed in 44 of the  77 individuals 
in whom it was  possible  to serotype. On  genotype analysis, 
Table 1. HCV Types  in  Hemophiliacs  as Detected by ELISA 
Serotypes and RFLP Genotypes 
Serotype 
1 2 3 Mixed Nonspecific 
Genotype 1 36 0 0 7 5 
2 5 2 0  3 2 
3 6 0 5  2 4 
4 2 0 0  0 2 
5 2 0 0  0 0 
Mixed 3 0 0  1 3 
PCR neg 3 0 0 0 3 
The ELISA does not detect HCV types 4 or 5. 
50% were  type 1, 13%  type 2, and 18% type 3. In addition, 
four patients  were  type  4 and  two  type 5. Seven patients  had 
a  mixed  infection by this  method (Table 1). Mixed infections 
and  HCV  genotypes 4 and 5 were  observed only  in  patients 
who  had received commercially derived  products. 
We  also  examined  the  relationship between HCV geno- 
type and human immunodeficiency  virus (HIV) antibody 
status. The incidence of coinfection with HIV among the 
three  HCV  genotypes 1, 2, and 3 was  27%, 25%, and 35%. 
respectively. 
In view of the  observed  discrepancies  between HCV sero- 
type and genotype, HCV virus sequencing was performed 
on samples  from seven such patients. For all  seven samples, 
identical  results  were  obtained  in the  genotype derived from 
RFLP  analysis  and that from direct sequencing. 
Relationship  Between  Liver  Histology  and  HCV  Genotype 
Cirrhosis  was present in 5 of 27 (19%) biopsy specimens 
of individuals  with type 1; in  2 of 9 (22%) individuals  with 
type 2, and in 5 of 8 (63%) with type 3 (Table 2). The 
incidence of cirrhosis  was significantly greater with type 3 
compared with non-type 3 HCV (5  of 8 v 8 of 34) [P  < 
,051. In patients with genotype 1 ,  cirrhosis  was  documented 
on biopsy at 12, 15, 20, and 21 years following the first 
exposure to pooled clotting factor concentrates, compared 
with patients with genotype 3, where it was found after 3, 
4, 6,  18, and  20 years. There  were  no significant differences 
between  the  HCV  groups with respect  to duration  of HCV 
infection from initial exposure, age, or in type or severity 
of hemostatic defect (results not given). In addition, there 
was no  apparent  relationship  between coexistent HIV  infec- 
tion and  the  presence of hepatic  cirrhosis. Two patients  were 
coinfected with the hepatitis  B  virus; in one  the  HCV geno- 
type was 1 and histology chronic persistent  hepatitis (CPH), 
while in the other the HCV genotype was 2 + 3 and the 
histology chronic  active hepatitis (CAH).  In  one patient with 
genotype 2 HCV,  alcohol  abuse  was believed to have  played 
a contributory role in  the development of cirrhosis. 
DISCUSSION 
The transmission of HCV to hemophiliacs by clotting  fac- 
tor concentrates in the period before  the introduction of ef- 
fective viral  inactivation procedures is  well  established. This 
occurred largely as a consequence of the very large donor 
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Table 2. HCV GenotvDes in Relation to Liver Histoloav 
Histology 
HCV Genotype 
CPH No. 
(%)* 
CAH No. 
(96) 
Cirrhosis 
No. (%) 
1 
2 
3 
4 
5 
1 + 2  
1 + 3  
Negative PCR 
15 (56) 
4 (44) 
3 (38) 
2  (66) 
1 
1 
1 
1 
7 (26) 
3  (33) 
0 
0 
0 
0 
0 
0 
* Percentage within each genotype. 
pool incorporated into individual batches of the concentrate. 
The infectivity of the  final material would also relate to the 
prevalence of HCV in the donor population. Because the 
prevalence of HCV among paid donors was greater than 
that among volunteer donors, it can be anticipated that the 
infectivity of commercial products derived from the former 
was greater than that of material obtained from the latter 
group. However, Kernoff et all3 and Fletcher et a l l 4  showed 
that the infectivity of National Health Service (volunteer) 
clotting factor concentrates given to previously untreated 
hemophiliacs was virtually 100%. 
There is now considerable evidence that hepatitis C, a 
single-stranded RNA virus, exhibits considerable sequence 
diversity, and recent phylogenetic analysis of the viral ge- 
nome indicates the presence at least six major genotypes of 
the virus.7 Studies from blood donors and from patients with 
non-A, non-B hepatitis indicate a widespread geographic 
distribution of HCV types 1 and 2. HCV type 3 has been 
frequently reported in the United States, Canada, Australia, 
E~rope', '~,' '  and Thailand.I7 
With respect to hemophilia, the geographic distribution of 
the virus and possible type-related differences in the natural 
history of the associated chronic liver disease are of consid- 
erable interest because the therapeutic materials are derived 
from donors throughout the world. Consequently, it can  be 
anticipated that the distribution of HCV types in infected 
hemophiliacs will relate directly to the source of their thera- 
peutic materials. 
The cohort of patients reported here have received a range 
of clotting factor concentrates derived from both volunteer 
and  paid donors. The former are UK-based and the latter are 
largely from the United States. The distribution of HCV 
genotypes 1,2, and 3 were 50%, 13%, and 18%, respectively. 
In addition, mixed infections were identified by both sero- 
typic (14%) and genotypic analysis (7%). This HCV geno- 
type distribution is markedly different from that of a recently 
described UK blood donor population in which  mixed infec- 
tions were not observed." Interestingly, in the patients re- 
ported here, mixed infections were confined to those who 
had received commercially derived products. 
An unexpected observation, confirmed by sequencing 
analysis, was the identification of HCV genotype 4 in four 
of our patients and genotype 5 in a further two. To date, both 
of these HCV genotypes show highly restricted geographic 
distributions in that type 4 has been reported from the Middle 
East and and type 5 occurs predominantly in South 
Africa,6 although recent reports indicate that it is present in 
low frequency in The Netherlands," Australia," and Can- 
ada.I6 Taken together, these two HCV genotypes comprise 
6.3% of the infective HCV agent in our patients. Therefore, 
it seems highly likely that this is a reflection of the source 
of the donor pool. Because our patients have received a 
number of different clotting factor concentrates, we are un- 
able to relate the transmission of these HCV genotypes to 
any particular product. However, infection with  HCV geno- 
types 4 and 5 was  confined to patients with hemophilia A. 
Although the numbers are small, it  is possible that commer- 
cial products were responsible for the transmission of these 
genotypes because hemophilia B patients were treated exclu- 
sively with UK-derived material, and these particular geno- 
types have not  been  identified in UK donors. 
In this cohort of hemophiliacs, some differences were ob- 
served between HCV serotype and genotype. This is  in con- 
trast to the situation in HCV-infected blood donors in  whom 
there is close agreement between the two assays. The ob- 
served differences in hemophiliacs is likely to relate to  their 
reinfection with different HCV types, which could differ in 
their replication rates and in their capacity to induce HCV 
antibody formation. The recent observation that changes in 
the major circulating HCV genotype can occur in some in- 
fected hemophiliacs (Simmonds, unpublished observation) 
may also provide some explanation for the observed discrep- 
ancies between  HCV serotype and genotype in our patients. 
Simmonds et a17 have suggested that the degree of se- 
quence variability of HCV  is sufficient to significantly alter 
the antigenic and biologic properties of the virus, and  they 
have demonstrated that in HCV antibody positive Scottish 
blood donors alanine aminotransferase levels are greater in 
individuals infected with HCV type 3 than in those with 
the more common type l infection. Other groups have also 
reported possible differences in the natural  history of differ- 
ent HCV serotypes and also in their responsiveness to inter- 
feron,20'22 but the adoption of different HCV classification 
systems by the various groups makes comparisons somewhat 
difficult. 
We have confirmed previous suggestions that  HCV geno- 
type 3 is associated with a more aggressive form of chronic 
liver disease than that associated with types 1 and 2.'' Be- 
cause there were no differences between the HCV genotype 
groups with respect to duration of exposure, coexistent HIV 
infection, age, and severity of hemophilia, we conclude that 
this effect is probably HCV-type specific. It was interesting 
that in three patients with type 3 HCV cirrhosis developed 
within 3 years of exposure to concentrates compared to pa- 
tients with type l, where  all cases developed after 12 years. 
Other groups have suggested severe liver disease occurs 
in relation to type 1 infections," especially type lb.'' How- 
ever, it should be appreciated that the natural history of 
HCV infection in hemophiliacs may differ from that of other 
groups because there are important differences with respect 
to viral load, mixed  HCV genotype infections, and immune 
suppression associated with clotting factor concentrates. The 
emergence of a relationship between a particular HCV geno- 
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type and progressive liver disease is highly complex and 
undoubtedly reflects a number of interrelated factors affect- 
ing virus-host interactions. 
There is increasing evidence that the natural history of 
HCV-related liver disease may be greatly influenced by  HCV 
genotype. The global distribution of a large number of geno- 
types and subtypes of HCV has resulted in a complex pattern 
of HCV infection in hemophiliacs treated with pooled 
plasma-derived products. In view of the growing evidence 
that the eventual clinical outcome, including interferon re- 
sponsiveness, of HCV infection may be influenced by HCV 
genotype, it seems clear that this will have considerable 
impact on the natural history of HCV-related chronic liver 
disease in hemophiliacs in different parts of the world. 
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